These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
236 related items for PubMed ID: 30099439
1. Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy. Tan L, Tang Y, Peng W, Mathew BS, Qin W. Kidney Blood Press Res; 2018; 43(4):1333-1343. PubMed ID: 30099439 [Abstract] [Full Text] [Related]
2. Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria. Pei G, Tan J, Tang Y, Tan L, Zhong Z, Zhou L, Chen C, Qin W. Medicine (Baltimore); 2020 Jun 12; 99(24):e20513. PubMed ID: 32541473 [Abstract] [Full Text] [Related]
3. Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria. Zhong Z, Tang Y, Tan J, Tan L, Pei G, Qin W. Int Urol Nephrol; 2021 Jan 12; 53(1):121-127. PubMed ID: 32944888 [Abstract] [Full Text] [Related]
4. The prognostic effect of immunosuppressive therapy in IgA nephropathy with stage 3 or 4 chronic kidney disease. Yang X, Ma F, Bai M, Wang Y, Jia Q, Dong R, Liu C, Sun S. Ren Fail; 2021 Aug 10; 43(1):1180-1187. PubMed ID: 34376108 [Abstract] [Full Text] [Related]
5. Immunosuppressant Agents as Add-On Therapy Failed to Improve the Outcome of Immunoglobulin A Nephropathy with Crescent Score C1. Bi X, Yu Y, Zhou S, Zhou Y, Zhao J, Xiong J. Nephron; 2024 Aug 10; 148(9):587-600. PubMed ID: 38723614 [Abstract] [Full Text] [Related]
6. Corticosteroids Improve Renal Survival: A Retrospective Analysis From Chinese Patients With Early-Stage IgA Nephropathy. Qin A, Pei G, Tang Y, Tan L, Wei X, Zhong Z, Zhou L, Chen C, Qin W. Front Med (Lausanne); 2020 Aug 10; 7():585859. PubMed ID: 33195345 [Abstract] [Full Text] [Related]
7. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial. Li S, Li JP. Trials; 2020 Jan 06; 21(1):31. PubMed ID: 31907076 [Abstract] [Full Text] [Related]
8. Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents. Chen J, Xu H, Peng Z, Lin L, Li C, Zhu X, Liu S. Clin Exp Nephrol; 2020 Jan 06; 24(1):73-81. PubMed ID: 31605314 [Abstract] [Full Text] [Related]
9. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide. Ma F, Yang X, Zhou M, Bai M, Zhao L, Li L, Dong R, Liu C, Li R, Sun S. J Nephrol; 2020 Dec 06; 33(6):1241-1250. PubMed ID: 32447619 [Abstract] [Full Text] [Related]
10. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Nephrol Dial Transplant; 2009 Dec 06; 24(12):3694-701. PubMed ID: 19628647 [Abstract] [Full Text] [Related]
11. Immunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group. Oruc A, Sumnu A, Turkmen A, Basturk T, Cebeci E, Turgutalp K, Cetinkaya H, Uzerk Kibar M, Seyahi N, Tatar E, Ergul M, Derici Ü, Aylı MD, Pınar M, Bakar B, Kazancıoglu R, Yıldız A, Dirim AB, Yılmaz Z, Turkmen K, Tunca O, Koc M, Kutlay S, Micozkadıoglu H, Azak A, Boztepe B, Ustundag S, Şafak Ozturk S, Unsal A, Karadag S, Sahin G, Yenigun EC, Eren N, Gullulu M, Gursu M, Ozturk S. Ren Fail; 2024 Dec 06; 46(1):2341787. PubMed ID: 38637275 [Abstract] [Full Text] [Related]
12. A validation study of crescents in predicting ESRD in patients with IgA nephropathy. Zhang X, Shi S, Ouyang Y, Yang M, Shi M, Pan X, Lv J, Wang Z, Ren H, Shen P, Wang W, Zhang H, Xie J, Chen N. J Transl Med; 2018 May 03; 16(1):115. PubMed ID: 29724226 [Abstract] [Full Text] [Related]
14. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy. Min L, Wang Q, Cao L, Zhou W, Yuan J, Zhang M, Che X, Mou S, Fang W, Gu L, Zhu M, Wang L, Yu Z, Qian J, Ni Z. Oncotarget; 2017 Jul 18; 8(29):48375-48384. PubMed ID: 28415636 [Abstract] [Full Text] [Related]
15. Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience. Wu H, Fang X, Xia Z, Gao C, Peng Y, Li X, Zhang P, Kuang Q, Wang R, Wang M. J Nephrol; 2020 Dec 18; 33(6):1263-1273. PubMed ID: 32507961 [Abstract] [Full Text] [Related]
16. Immunosuppressive agents for treating IgA nephropathy. Vecchio M, Bonerba B, Palmer SC, Craig JC, Ruospo M, Samuels JA, Molony DA, Schena FP, Strippoli GF. Cochrane Database Syst Rev; 2015 Aug 03; (8):CD003965. PubMed ID: 26235292 [Abstract] [Full Text] [Related]
17. A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study. Chen S, Yin Q, Ren S, Zhong X, Wang W, Li G, Wang L. Sci Rep; 2018 Sep 12; 8(1):13662. PubMed ID: 30209279 [Abstract] [Full Text] [Related]
18. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study. Yu MY, Kim YC, Koo HS, Chin HJ. PLoS One; 2017 Sep 12; 12(11):e0188375. PubMed ID: 29155873 [Abstract] [Full Text] [Related]
19. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial. Hou FF, Xie D, Wang J, Xu X, Yang X, Ai J, Nie S, Liang M, Wang G, Jia N, MAIN Trial Investigators. JAMA Netw Open; 2023 Feb 01; 6(2):e2254054. PubMed ID: 36745456 [Abstract] [Full Text] [Related]
20. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study. Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts IS, Cattran D, Coppo R, VALIGA study of the ERA-EDTA Immunonephrology Working Group. J Am Soc Nephrol; 2015 Sep 01; 26(9):2248-58. PubMed ID: 25677392 [Abstract] [Full Text] [Related] Page: [Next] [New Search]